What is HC Wainwright’s Forecast for FENC Q1 Earnings?

Fennec Pharmaceuticals Inc (NASDAQ:FENC) – HC Wainwright lifted their Q1 2025 earnings per share estimates for Fennec Pharmaceuticals in a report released on Tuesday, March 11th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($0.13) per share for the quarter, up from their previous estimate of ($0.20). HC Wainwright currently has a “Buy” rating and a $13.00 price target on the stock. The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is ($0.11) per share. HC Wainwright also issued estimates for Fennec Pharmaceuticals’ Q2 2025 earnings at ($0.10) EPS, Q3 2025 earnings at ($0.06) EPS, Q4 2025 earnings at $0.02 EPS, FY2025 earnings at ($0.28) EPS and FY2026 earnings at $0.63 EPS.

Other equities analysts have also issued research reports about the company. Wedbush reissued an “outperform” rating and set a $13.00 target price on shares of Fennec Pharmaceuticals in a research note on Monday. Stephens upgraded Fennec Pharmaceuticals to a “strong-buy” rating in a research note on Monday, November 18th.

Fennec Pharmaceuticals Stock Down 5.7 %

Shares of NASDAQ:FENC opened at $6.13 on Thursday. The stock has a market cap of $168.96 million, a P/E ratio of -61.29 and a beta of 0.36. Fennec Pharmaceuticals has a 52-week low of $3.96 and a 52-week high of $11.49. The business has a fifty day moving average of $6.39 and a two-hundred day moving average of $5.63.

Insider Buying and Selling at Fennec Pharmaceuticals

In other Fennec Pharmaceuticals news, Director Rosty Raykov sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $6.66, for a total transaction of $66,600.00. Following the sale, the director now owns 76,294 shares in the company, valued at $508,118.04. This represents a 11.59 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Over the last 90 days, insiders sold 31,186 shares of company stock valued at $203,389. Company insiders own 10.98% of the company’s stock.

Hedge Funds Weigh In On Fennec Pharmaceuticals

Several institutional investors have recently made changes to their positions in the stock. Rosalind Advisors Inc. acquired a new stake in shares of Fennec Pharmaceuticals during the 4th quarter valued at $7,962,000. Solas Capital Management LLC raised its holdings in Fennec Pharmaceuticals by 17.0% during the fourth quarter. Solas Capital Management LLC now owns 2,250,919 shares of the company’s stock valued at $14,226,000 after buying an additional 327,383 shares in the last quarter. Advantage Alpha Capital Partners LP bought a new position in shares of Fennec Pharmaceuticals in the third quarter worth about $264,000. Clayton Partners LLC acquired a new stake in Fennec Pharmaceuticals during the fourth quarter worth about $256,000. Finally, Barclays PLC boosted its holdings in Fennec Pharmaceuticals by 274.3% during the third quarter. Barclays PLC now owns 31,319 shares of the company’s stock valued at $157,000 after purchasing an additional 22,951 shares in the last quarter. 55.51% of the stock is owned by institutional investors.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.